Name: Calciphylaxis Treatment Market Size and Trends
Creator: Coherent Market Insights
License: https://www.coherentmarketinsights.com/privacy-policy
Keywords: Calciphylaxis Treatment Market, Calciphylaxis Treatment Market Report, Calciphylaxis Treatment Industry Report, Calciphylaxis Treatment Market Size, Calciphylaxis Treatment Market Share, Calciphylaxis Treatment Market Analysis, Calciphylaxis Treatment Market Growth, Calciphylaxis Treatment Market Trends, Calciphylaxis Treatment Market Overview, Calciphylaxis Treatment Market Forecast

Calciphylaxis Treatment Market, by Treatment (Drug Therapy, and Hyperbaric Oxygen Therapy), by End User (Hospital and Clinics, Homecare, and Ambulatory Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Trends, and Forecast to 2026

Published In : Oct 2018

Code : CMI2251

Pages :165

Formats :

Excel and PDF

Industry : Pharmaceutical

Calciphylaxis Treatment MarketSize and Trends

The global calciphylaxis treatment market size was valued at US$ 1,097.7 million in 2017 and is expected to witness a CAGR of 9.6% over the forecast period (2018 – 2026).

Global Calciphylaxis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%)

Source: Coherent Market Insights Analysis (2018)

Increasing clinical trials in the field of calciphylaxis is expected to drive the calciphylaxis treatment market revenue

According to the Journal of General Internal Medicine 2014 study, calciphylaxis has an increasing incidence trend and a 50% mortality rate within the first year of onset. High prevalence of kidney disease is a major factor for incidences of calciphylaxis. According to the National Institute of Diabetes and Digestive and Kidney Diseases Health Information Center, in 2016, over 661,000 Americans had kidney failure and 468,000 of these patients were on dialysis.

Various academic research institutes and companies are focused on developing suitable treatment for calciphylaxis. For instance in March 2018, Sanifit successfully completed a Phase II trial of the first effective treatment for calciphylaxis. Moreover, in 2014, researchers at the National Kidney Foundation reported successful application of intravenous (IV) pamidronate to treat calciphylaxis in patients with End-Stage Renal Disease (ESRD).